High hepatitis C virus prevalence among drug users in Iran: Systematic review and meta-analysis of epidemiological evidence (2001-2012)

International Journal of Infectious Diseases

Volumn 40, Issue , 2015, Pages 116-130

  Malekinejad, Mohsen ^a   Navadeh, Soodabeh ^a,b   Lotfizadeh, Ali ^a   Rahimi Movaghar, Afarin ^c   Amin Esmaeili, Masoumeh ^d   Noroozi, Alireza ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug use; Harm reduction; Hepatitis B; Hepatitis C; HIV; Iran

Indexed keywords

CONFIDENCE INTERVAL; DRUG ABUSE; DRUG USE; EPIDEMIOLOGICAL DATA; HARM REDUCTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INJECTION; IRAN; META ANALYSIS; MIXED INFECTION; PREVALENCE; PRISON; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; COMPLICATION; HEPACIVIRUS; HIV INFECTIONS; ISOLATION AND PURIFICATION; SUBSTANCE ABUSE;

HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMANS; IRAN; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84946411425     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2015.09.022     Document Type: Review

References (90)

1. Aceijas C., Rhodes T. Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007, 18:352-358.
2. Hepatitis C: Fact Sheet No. 164 2012, World Health Organization, WHO, Geneva.
3. Hepatitis C FAQs for health professionals 2014, US Centers for Disease Control and Prevention, CDC, Atlanta, GA.
4. Coffin P.O., Scott J.D., Golden M.R., Sullivan S.D. Cost-effectiveness and population outcomes of general population screening for hepatitis C. Clin Infect Dis 2012, 54:1259-1271.
5. Friedland G. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr 2010, 55(Suppl 1):S37-S42.
6. Nelson P.K., Mathers B.M., Cowie B., Hagan H., Des Jarlais D., Horyniak D., et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011, 378:571-583.
7. Walsh N., Maher L. HIV and viral hepatitis C coinfection in people who inject drugs: implications of new direct acting antivirals for hepatitis C virus treatment. Curr Opin HIV AIDS 2012, 7:339-344.
8. World drug report 2014 2014, United Nations Office on Drugs and Crime, UNODC, Vienna.
9. Edlin B.R., Seal K.H., Lorvick J., Kral A.H., Ciccarone D.H., Moore L.D., et al. Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?. N Engl J Med 2001, 345:211-215.
10. Edlin B.R., Kresina T.F., Raymond D.B., Carden M.R., Gourevitch M.N., Rich J.D., et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005, 40(Suppl 5):S276-S285.
11. Hagan H., Pouget E.R., Des Jarlais D.C. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infect Dis 2011, 204:74-83.
12. Page-Shafer K., Morris M., Hahn J.A., Maher L., Prins M. Injection drug use and hepatitis C virus infection in young adults: using research evidence to inform prevention. Clin Infect Dis 2013, 57(Suppl 2):S32-S38.
13. Page-Shafer K., Hahn J.A., Lum P.J. Preventing hepatitis C virus infection in injection drug users: risk reduction is not enough. AIDS 2007, 21:1967-1969.
14. Shokoohi M., Baneshi M.R., Haghdoost A.A. Estimation of the active network size of Kermanian males. Addict Health 2010, 2:81-88.
15. Rahimi-Movaghar A., Vameghi M. Drug addiction 2011, Rahman Institute, Tehran, Iran.
16. Rahimi-Movaghar A., Sharifi V., Motevalian S., Amin-Esmaeili M., Rad Goodarzi R., Hefazi M. Final report for project, Iran Mental Health Survey (Iran-MHS). Ministry of Health and Tehran University of Medical Sciences 2012.
17. Malekinejad M., Vazirian M. Transition to injection amongst opioid users in Iran: implications for harm reduction. Int J Drug Policy 2012, 23:333-337.
18. Rahimi-Movaghar A., Amin-Esmaeili M., Haghdoost A.A., Sadeghirad B., Mohraz M. HIV prevalence amongst injecting drug users in Iran: a systematic review of studies conducted during the decade 1998-2007. Int J Drug Policy 2012, 23:271-278.
19. Razzaghi E., Nassirimanesh B., Afshar P., Ohiri K., Claeson M., Power R. HIV/AIDS harm reduction in Iran. Lancet 2006, 368:434-435.
20. Alavian S.M., Adibi P., Zali M.R. Hepatitis C virus in Iran: epidemiology of an emerging infection. Arch Iranian Med 2005, 8:84-90.
21. Rahimi-Movaghar A., Amin-Esmaeili M., Shadloo B., Noroozi A., Malekinejad M. Transition to injecting drug use in Iran: a systematic review of qualitative and quantitative evidence. Int J Drug Policy 2015, 26(9):808-819.
22. Hoy D., Brooks P., Woolf A., Blyth F., March L., Bain C., et al. Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol 2012, 65:934-939.
23. Alipour A., Haghdoost A.A., Sajadi L., Zolala F. HIV prevalence and related risk behaviours among female partners of male injecting drugs users in Iran: results of a bio-behavioural survey, 2010. Sex Transm Infect 2013, 89(Suppl 3):iii41-iii44.
24. Amin-Esmaeili M., Rahimi-Movaghar A., Razaghi E.M., Baghestani A.R., Jafari S. Factors correlated with hepatitis C and B virus infections among injecting drug users in Tehran, IR Iran. Hepat Mon 2012, 12:23-31.
25. Amini S., Andalibi Mahmoodabadi S., Lamian S., Joulaie M., Mahmoodi Farahani M. Prevalence of Hepatitis G virus (HGV) in high-risk groups and blood donors in Tehran, Iran. Iranian Journal of Public Health 2005, 34:41-46.
26. Eskandarieh S., Nikfarjam A., Tarjoman T., Nasehi A., Jafari F., Saberi-Zafarghandi M.B. Descriptive aspects of injection drug users in Iran's national harm reduction program by methadone maintenance treatment. Iran J Public Health 2013, 42:588-593.
27. Honarvar B., Odoomi N., Moghadami M., Afsar Kazerooni P., Hassanabadi A., Zare Dolatabadi P., et al. Blood-borne hepatitis in opiate users in Iran: a poor outlook and urgent need to change nationwide screening policy. PLoS One 2013, 8:e82230.
28. Hosseini M., SeyedAlinaghi S., Kheirandish P., Esmaeli Javid G., Shirzad H., Karami N., et al. Prevalence and correlates of co-infection with human immunodeficiency virus and hepatitis C virus in male injection drug users in Iran. Arch Iran Med 2010, 13:318-323.
29. Imani R., Karimi A., Rouzbahani R., Rouzbahani A. Seroprevalence of HBV, HCV and HIV infection among intravenous drug users in Shahr-e-Kord, Islamic Republic of Iran. East Mediterr Health J 2008, 14:1136-1141.
30. Keramat F., Eini P., Majzoobi M.M. Seroprevalence of HIV, HBV and HCV in persons referred to Hamadan Behavioral Counseling Center, west of Iran. Iran Red Crescent Med J 2011, 13:42-46.
31. Kheirandish P., SeyedAlinaghi S., Jahani M., Shirzad H., Seyed Ahmadian M., Majidi A., et al. Prevalence and correlates of hepatitis C infection among male injection drug users in detention, Tehran, Iran. J Urban Health 2009, 86:902-908.
32. Malekinejad M., Johnston L.G., Kendall C., Kerr L.R., Rifkin M.R., Rutherford G.W. Using respondent-driven sampling methodology for HIV biological and behavioral surveillance in international settings: a systematic review. AIDS Behav 2008, 12(4 Suppl):S105-S130.
33. Mir-Nasseri M., Poustchi H., Nasseri-Moghadam S., Tavakkoli H., Mohammadkhani A., Afshar P., et al. Hepatitis C seroprevalence among intravenous drug users in Tehran. Journal of Research in Medical Sciences 2008, 13:295-302.
34. Mir-Nasseri M.M., Mohammadkhani A., Tavakkoli H., Ansari E., Poustchi H. Incarceration is a major risk factor for blood-borne infection among intravenous drug users: incarceration and blood borne infection among intravenous drug users. Hepat Mon 2011, 11:19-22.
35. Mirahmadizadeh A.R., Majdzadeh R., Mohammad K., Forouzanfar M. Prevalence of HIV and hepatitis C virus infections and related behavioral determinants among injecting drug users of drop-in centers in Iran. Iran Red Crescent Med J 2009, 11:325-329.
36. Nobari R.F., Meshkati M., Ataei B., Yazdani M.R., Heidari K., Kassaian N., et al. Identification of patients with hepatitis C virus infection in persons with background of intravenous drug use: the first community announcement-based study from Iran. Int J Prev Med 2012, 3(Suppl 1):S170-S175.
37. Nokhodian Z., Meshkati M., Adibi P., Ataei B., Kassaian N., Yaran M., et al. Hepatitis C among intravenous drug users in Isfahan, Iran: a study of seroprevalence and risk factors. Int J Prev Med 2012, 3(Suppl 1):S131-S138.
38. Rahimi-Movaghar A., Razaghi E.M., Sahimi-Izadian E., Amin-Esmaeili M. HIV, hepatitis C virus, and hepatitis B virus co-infections among injecting drug users in Tehran, Iran. Int J Infect Dis 2010, 14:e28-e33.
39. Rahnama R., Mohraz M., Mirzazadeh A., Rutherford G., McFarland W., Akbari G., et al. Access to harm reduction programs among persons who inject drugs: findings from a respondent-driven sampling survey in Tehran. Iran. Int J Drug Policy 2014, 25(4):717-723.
40. Ramezani A., Amirmoezi R., Volk J.E., Aghakhani A., Zarinfar N., McFarland W., et al. HCV, HBV, and HIV seroprevalence, coinfections, and related behaviors among male injection drug users in Arak, Iran. AIDS Care 2014, 26:1122-1126.
41. Sarkari B., Eilami O., Khosravani A., Sharifi A., Tabatabaee M., Fararouei M. High prevalence of hepatitis C infection among high risk groups in Kohgiloyeh and Boyerahmad Province, southwest Iran. Arch Iran Med 2012, 15:271-274.
42. Sayad B., Saeed F., Keyvani H., Rezaii M., Asadi T., Vaziri S., et al. Seroepidemiology of hepatitis C in Kermanshah (west of Iran, 2006). Hepat Mon 2008, 8:141-146.
43. Talaie H., Shadnia S.H., Okazi A., Pajouhmand A., Hasanian H., Arianpoor H. The prevalence of hepatitis B, hepatitis C and HIV infections in non-IV drug opioid poisoned patients in Tehran-Iran. Pak J Biol Sci 2007, 10:220-224.
44. Zamani S., Ichikawa S., Nassirimanesh B., Vazirian M., Ichikawa K., Gouya M.M., et al. Prevalence and correlates of hepatitis C virus infection among injecting drug users in Tehran. Int J Drug Policy 2007, 18:359-363.
45. Zamani S., Radfar R., Nematollahi P., Fadaie R., Meshkati M., Mortazavi S., et al. Prevalence of HIV/HCV/HBV infections and drug-related risk behaviours amongst IDUs recruited through peer-driven sampling in Iran. Int J Drug Policy 2010, 21:493-500.
46. Ataei B., Meshkati M., Karimi A., Yaran M., Kassaian N., Nokhodian Z., et al. Hepatitis C screening in intravenous drug users in Golpayegan, Isfahan through community announcement: pilot study. Journal of Isfahan Medical School 2011, 28(Special Issue on Hepatitis C):1581-1586.
47. Azizi A., Amirian F., Amirian M. Prevalence and associated factors of hepatitis C in self-introduced substance abusers. Hayat 2011, 17:55-61.
48. Fadaei Nobari R., Meshkati M., Ataei B., Heidari K., Kassaian N., Nokhodian Z., et al. Positive hepatitis C virus antibody in cases with history of intravenous drug abuse via community announcement: a useful experience. Journal of Isfahan Medical School 2011, 28(Special Issue on Hepatitis C):1546-1552.
49. Imani R., Karimi A., Kassaian N. The relevance of related-risk behaviors and seroprevalence of HBV, HCV and HIV infection in intravenous drug users from Shahrekord, Iran, 2004. Journal of Shahrekord University of Medical Sciences 2006, 8:58-62.
50. Khodadadi-zadeh A., Nadimi A., Esmaeili S., Hosseini H., Shabani Z. The prevalence of HIV, HBV and HCV in narcotic addicted persons referred to the outpatient clinic of Rafsanjan University of Medical Sciences in 2003. Journal of Rafsanjan University of Medical Sciences 2006, 5:23-30.
51. Meshkati M., Ataei B., Nokhaodian Z., Yaran M., Babak A., Asgarian zadeh M., et al. Hepatitis C screening in Isfahan drop in centers: an experience description. Journal of Isfahan Medical School 2011, 28(Special Issue on Hepatitis C):1553-1559.
52. Mir Nasseri M.M., Poustchi H., Nasseri Moghadam S., Nouraie S.M., Tahaghoghi S., Afshar P., et al. HCV in intravenous drug users. Govaresh 2005, 10:80-86.
53. Noroozi A., Radfar R., Alam Mehrjerdi Z., Motevalian A., Haghdoost A., Nematollahi P., et al. Bio-behavioral survey among injecting drug users and their sexual partners in Karaj. Isfahan and Gorgan. 2011, Final Report, United Nation Office of Drug and Crime. Can be accessed via https://www.unodc.org/documents/islamicrepublicofiran//Couple_BSS_Final_Report.pdf. Accessed Aug 15, 2015.
54. Rostami Jalilian M., Omid Ghaemi M., Kasaeian N. Relationship of hepatitis B and C with deep vein thrombosis in IV drug abusers. Journal of Military Medicine 2006, 8:78-81.
55. Malekinejad M. Assessment of the use of respondent-driven sampling for studying populations most at risk of HIV infection 2008, Doctoral Dissertation. School of Public Health, University of California, Berkeley, USA.
56. Alter M.J. HCV routes of transmission: what goes around comes around. Semin Liver Dis 2011, 31:340-346.
57. Degenhardt L., Whiteford H.A., Ferrari A.J., Baxter A.J., Charlson F.J., Hall W.D., et al. Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. Lancet 2013, 382:1564-1574.
58. Kimber J., Palmateer N., Hutchinson S., Hickman M., Goldberg D., Rhodes T. Harm reduction among injecting drug users-evidence of effectiveness. European Monitoring Centre for Drugs and Drug Addiction 2010, 115-163.
59. Palmateer N., Kimber J., Hickman M., Hutchinson S., Rhodes T., Goldberg D. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews. Addiction 2010, 105:844-859.
60. Van Den Berg C., Smit C., Van Brussel G., Coutinho R., Prins M., Amsterdam C. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102:1454-1462.
61. De Carli G., Puro V., Ippolito G. Studio Italiano Rischio Occupazionale da HIVG. Risk of hepatitis C virus transmission following percutaneous exposure in healthcare workers. Infection 2003, 31(Suppl 2):22-27.
62. Hudgens M.G., Longini I.M., Vanichseni S., Hu D.J., Kitayaporn D., Mock P.A., et al. Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand. Am J Epidemiol 2002, 155:159-168.
63. Kaplan E.H., Heimer R. A model-based estimate of HIV infectivity via needle sharing. J Acquir Immune Defic Syndr 1992, 5:1116-1118.
64. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002, 155:645-653.
65. Vidal-Trecan G.M., Varescon-Pousson I., Gagniere B., Tcherny-Lessenot S., Madariaga E., Boissonnas A. Association between first injection risk behaviors and hepatitis C seropositivity among injecting drug users. Ann Med Interne (Paris) 2002, 153:219-225.
66. Zhou F., Ma Z.E., Hu W., Feng Z.L., Chen K.L., Qin G.M., et al. [Study on the relationship between hepatitis C virus infection and sharing injection equipment, sexual behavior among injecting drug users]. Zhonghua Liu Xing Bing Xue Za Zhi 2004, 25:329-332.
67. Sutton A.J., Gay N.J., Edmunds W.J., Hope V.D., Gill O.N., Hickman M. Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales. BMC Infect Dis 2006, 6:93.
68. Vickerman P., Hickman M., Judd A. Modelling the impact on hepatitis C transmission of reducing syringe sharing: London case study. Int J Epidemiol 2007, 36:396-405.
69. Hickman M., Hope V., Brady T., Madden P., Jones S., Honor S., et al. Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004. J Viral Hepat 2007, 14:645-652.
70. Wiessing L., Ferri M., Grady B., Kantzanou M., Sperle I., Cullen K.J., et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One 2014, 9:e103345.
71. National AIDS Committee Secretariat 2012, Islamic Republic of Iran progress report on monitoring of the United Nations General Assembly Special Session on HIV and AIDS, Ministry of Health and Medical Education, Islamic Republic of Iran.
72. Barreiro P., Vispo E., Labarga P., Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis 2012, 32:138-146.
73. Aceti A., Pasquazzi C., Zechini B., De Bac C., Group L. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002, 29:41-48.
74. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., Jurriaans S., Weel J., van Leeuwen R., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000, 14:2895-2902.
75. Torti C., Lapadula G., Casari S., Puoti M., Nelson M., Quiros-Roldan E., et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis 2005, 5:58.
76. Taylor L.E., Swan T., Matthews G.V. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. Clin Infect Dis 2013, 57(Suppl 2):S118-S124.
77. Alter M.J. Hepatitis C virus infection in the United States. J Hepatol 1999, 31(Suppl 1):88-91.
78. Frederick T., Burian P., Terrault N., Cohen M., Augenbraun M., Young M., et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009, 23:915-923.
79. Feldman J.G., Minkoff H., Landesman S., Dehovitz J. Heterosexual transmission of hepatitis C, hepatitis B, and HIV-1 in a sample of inner city women. Sex Transm Dis 2000, 27:338-342.
80. Romanowski B., Preiksaitis J., Campbell P., Fenton J. Hepatitis C seroprevalence and risk behaviors in patients attending sexually transmitted disease clinics. Sex Transm Dis 2003, 30:33-38.
81. Smikle M., Dowe G., Hylton-Kong T., Williams E. Hepatitis B and C viruses and sexually transmitted disease patients in Jamaica. Sex Transm Infect 2001, 77:295-296.
82. Thomas D.L., Cannon R.O., Shapiro C.N., Hook E.W., Alter M.J., Quinn T.C. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis 1994, 169:990-995.
83. Weisbord J.S., Trepka M.J., Zhang G., Smith I.P., Brewer T. Prevalence of and risk factors for hepatitis C virus infection among STD clinic clientele in Miami, Florida. Sex Transm Infect 2003, 79:E1.
84. Amin-Esmaeili M., Rahimi-Movaghar A., Haghdoost A.A., Mohraz M. Evidence of HIV epidemics among non-injecting drug users in Iran: a systematic review. Addiction 2012, 107:1929-1938.
85. Latkin C.A., Vlahov D., Anthony J.C. Socially desirable responding and self-reported HIV infection risk behaviors among intravenous drug users. Addiction 1993, 88:517-526.
86. Xia X., Luo J., Bai J., Yu R. Epidemiology of hepatitis C virus infection among injection drug users in China: systematic review and meta-analysis. Public Health 2008, 122:990-1003.
87. Aspinall E.J., Corson S., Doyle J.S., Grebely J., Hutchinson S.J., Dore G.J., et al. Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis 2013, 57(Suppl 2):S80-S89.
88. Hellard M., Sacks-Davis R., Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009, 49:561-573.
89. Martin N.K., Vickerman P., Grebely J., Hellard M., Hutchinson S.J., Lima V.D., et al. Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013, 58:1598-1609.
90. Zeiler I., Langlands T., Murray J.M., Ritter A. Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 2010, 110:228-233.